Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 1280
118th Congress(2023-2024)
TRANQ Research Act of 2023
Introduced
Introduced
Introduced in Senate on Apr 25, 2023
Overview
Text
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
S. 1280 (Introduced-in-Senate)


118th CONGRESS
1st Session
S. 1280


To require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.

IN THE SENATE OF THE UNITED STATES

April 25, 2023

Mr. Cruz (for himself and Mr. Welch) introduced the following bill; which was read twice and referred to the Committee on Commerce, Science, and Transportation

A BILL

To require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Testing, Rapid Analysis, and Narcotic Quality Research Act of 2023” or the “TRANQ Research Act of 2023”.

SEC. 2. Xylazine detection and analysis.

(a) Definitions.—In this section:

(1) DIRECTOR.—The term “Director” means the Director of the National Institute of Standards and Technology.

(2) FEDERAL LABORATORY.—The term “Federal laboratory” has the meaning given such term in section 4 of the Stevenson-Wydler Technology Innovation Act of 1980 (15 U.S.C. 3703).

(3) INSTITUTE.—The term “Institute” means the National Institute of Standards and Technology.

(4) INSTITUTION OF HIGHER EDUCATION.—The term “institution of higher education” has the meaning given such term in section 101 of the Higher Education Act of 1965 (19 U.S.C. 1001).

(5) NONPROFIT ORGANIZATION.—The term “nonprofit organization” means an organization described in section 501(c)(3) of the Internal Revenue Code of 1986 and exempt from tax under section 501(a) of such code.

(6) XYLAZINE.—The term “xylazine” means the nonopioid tranquilizer methyl benzene compound frequently used in veterinary medicine as an emetic and sedative with analgesic and muscle relaxant properties.

(b) In general.—The Director shall—

(1) support intramural basic measurement science and research of the Institute to advance—

(A) analytical methods to identify, understand, differentiate, and categorize illicit drugs containing xylazine, novel synthetic opioids, or other emerging substances of concern;

(B) measurement technologies to shorten analysis timelines and enhance narcotic and opioid detection and analysis capabilities in illicit drugs;

(C) new data tools, techniques, and processes to identify and publicly disclose relevant information concerning illicit drugs containing xylazine, novel synthetic opioids, or other emerging substances of concern; and

(D) all other areas determined by the Director to be critical to the development and deployment of technologies to measure and analyze the presence of xylazine, novel synthetic opioids, and other emerging substances of concern in illicit drugs;

(2) support activities to inform and expand the development of near-real time spectrometry capabilities regarding xylazine, novel synthetic opioids, and other emerging compounds in illicit drugs;

(3) convene the private sector, institutions of higher education, nonprofit organizations, Federal laboratories, and other Federal agencies engaged in the analysis of illicit drugs to develop coordinated strategies and voluntary best practices for the safe handling, transport, and analysis of illicit drugs containing xylazine, novel synthetic opioids, or other emerging substances of concern;

(4) establish or expand collaborative partnerships or consortia with other government agencies engaged in counternarcotic research and development, institutions of higher education, Federal laboratories, and the private sector to enhance narcotic and opioid detection and analysis capabilities regarding xylazine, novel synthetic opioids, and other emerging substances of concern in illicit drugs; and

(5) provide opportunities for graduate and postgraduate research on the detection and identification of xylazine, novel synthetic opioids, and other emerging substances of concern in illicit drugs.

(c) Controls.—In carrying out activities under this section, the Director shall ensure proper security controls are implemented to protect sensitive information, as appropriate.

(d) Report.—Not later than 1 year after the date of the enactment of this Act, the Director shall submit to the Committee on Commerce, Science, and Transportation of the Senate and the Committee on Science, Space, and Technology of the House of Representatives a report on the implementation of this section. Such report may include recommendations for legislative action to improve the ability of the Director to carry out this section.